Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients…
Vir Biotechnology Launches Phase 3 ECLIPSE Program for Chronic Hepatitis Delta Treatment Vir Biotechnology, Inc. has officially enrolled its first patient in the Phase 3 ECLIPSE registrational program, a significant step in evaluating the efficacy and safety of the combination…
Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence Cellares, the first Integrated Development and Manufacturing Organization and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the…
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel…
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics, Inc. a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and…
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB Two River, LLC and Vida Ventures both part of the Bellco Health ecosystem, acknowledged the announced acquisition of Candid…
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company…
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner’s National Priority Voucher Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration…
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain…
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 Ironwood Pharmaceuticals, Inc. a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and…
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for…
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, announced that the…